Skip to content

Duodenal Exclusion for the Treatment of Type 2 Diabetes

Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00534547
Enrollment
0
Registered
2007-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2015-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The purpose of this study is to investigate the role of an experimental surgery that may offer better short and long-term control of T2DM in select patients who have not achieved adequate blood sugar control with regular means.

Interventions

duodenal-jejunal bypass

Sponsors

Medtronic - MITG
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Age between 20 and 50 years old; * BMI between 27 and 34.9; * Oral agents or insulin to control T2DM; * Inadequate control of diabetes as defined as HbA1c\>8.0% but \<10% * Understanding of the mechanisms of action of the treatment

Exclusion criteria

* More than 5 years of T2DM diagnosis; * C-peptide \<1pg/ml (off insulin) * Previous abdominal operations; * History of gastritis * History of GERD * History of peptic ulcer disease * Inflammatory bowel disease * Coagulopathy; * Liver cirrhosis; * Unable to comply with study requirements, follow-up schedule or give valid informed consent; * Currently pregnant (pregnancy test required for confirmation for those of child bearing years) * Patient is not available for programmed follow-up during the study period * Patient is unwilling to forgo good samaritan blood donation during the study period

Design outcomes

Primary

MeasureTime frame
Treatment success based on patients' glycemic control12 Months

Secondary

MeasureTime frame
Physiologic Measurements, Comorbidity improvement, Improvement in QOL12 Months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026